Roche Executive Casts Doubt on Possibility of Alexion Pharmaceuticals Inc. Buyout

Published: Sep 13, 2013

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Treating ultra-rare diseases is a distinct business from Roche's (ROG.VX) current area of expertise, the Swiss group's head of pharmaceuticals said, in comments that may cast doubt on its interest in Alexion Pharmaceuticals (ALXN.O).

Help employers find you! Check out all the jobs and post your resume.

Back to news